Adverse drug reactions and off-label and unlicensed medicines in children: A nested case-control study of inpatients in a pediatric hospital

BMC Medicine

Volumn 11, Issue 1, 2013, Pages

  Bellis, Jennifer R ^b   Kirkham, Jamie J ^a   Thiesen, Signe ^a   Conroy, Elizabeth J ^a   Bracken, Louise E ^b   Mannix, Helena L ^b   Bird, Kim A ^b   Duncan, Jennifer C ^b   Peak, Matthew ^b   Turner, Mark A ^a   Smyth, Rosalind L ^c   Nunn, Anthony J ^a   Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adverse drug reactions; Off label; Pediatrics; Prescribing; Unlicensed

Indexed keywords

CEFALEXIN; CEFOTAXIME; CEFUROXIME; CHLORPHENIRAMINE; CODEINE PHOSPHATE; DEXAMETHASONE; DIAZEPAM; DICLOFENAC; FENTANYL; FUROSEMIDE; IBUPROFEN; LACTULOSE; METRONIDAZOLE; MORPHINE; ONDANSETRON; PARACETAMOL; RANITIDINE; SALBUTAMOL;

ADOLESCENT; ADVERSE DRUG REACTION; AGE DISTRIBUTION; ARTICLE; BODY WEIGHT; CHILD; COHORT ANALYSIS; FEMALE; HOSPITAL PATIENT; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEWBORN; OFF LABEL DRUG USE; PEDIATRIC HOSPITAL; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SCHOOL CHILD;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENGLAND; FEMALE; HOSPITALS, PEDIATRIC; HUMANS; INFANT; INPATIENTS; MALE; OFF-LABEL USE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84887977963     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-11-238     Document Type: Article

References (20)

1. Kimland E, Odlind V. Off-label drug use in pediatric patients. Clin Pharmacol Ther 2012, 91:755-758. 10.1038/clpt.2012.37, 22513307.
2. Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf 2006, 5:703-718. 10.1517/14740338.5.5.703, 16907660.
3. The European Parliament and the Council of the European Union Regulation (EC) no 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Off J Eur Union 2006, 49:1-19. The European Parliament and the Council of the European Union.
4. S. 650--108th Congress Pediatric Research Equity Act of 2003. 2003, http://www.govtrack.us/congress/bills/108/s650 (Accessed 4 March 2013), S. 650--108th Congress.
5. Turner S, Nunn A, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999, 88:965-968. 10.1111/j.1651-2227.1999.tb00191.x, 10519338.
6. Mason J, Pirmohamed M, Nunn T. Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. Eur J Clin Pharmacol 2012, 68:21-28. 10.1007/s00228-011-1097-1, 21779968.
7. Gallagher RM, Kirkham JJ, Mason JR, Bird KA, Williamson PR, Nunn AJ, Turner MA, Smyth RL, Pirmohamed M. Development and inter-rater reliability of the Liverpool Adverse Drug Reaction Causality Assessment Tool. PLoS One 2011, 6:e28096. 10.1371/journal.pone.0028096, 3237416, 22194808.
8. DataPharm Communications Ltd Electronic Medicines Compendium. http://www.medicines.org.uk/EMC/default.aspx. (Accessed 4 March2013), DataPharm Communications Ltd.
9. Paediatric Formulary Committee BNF for Children 2009/2010, London: BMJ Group, Pharmaceutical Press, and RCPCH Publications, Paediatric Formulary Committee.
10. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008, 61:344-349. 10.1016/j.jclinepi.2007.11.008, 18313558.
11. Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, Knoeppel C, Seyberth H, Pandolfini C, Raffaelli MP, Rocchi F, Bonati M, TJong G, de Hoog M, van den Anker J. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ 2000, 320:79-82. 10.1136/bmj.320.7227.79, 27251, 10625257.
12. Jong GWT, Vulto AG, De Hoog M, Schimmel KJM, Tibboel D, Van Den Anker JN. A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital. Pediatrics 2001, 108:1089-1093. 10.1542/peds.108.5.1089, 11694685.
13. Neubert A, Dormann H, Weiss J, Egger T, Criegee-Rieck M, Rascher W, Brune K, Hinz B. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf 2004, 27:1059-1067. 10.2165/00002018-200427130-00006, 15471510.
14. Santos D, Clavenna A, Bonati M, Coelho H. Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil. Eur J Clin Pharmacol 2008, 64:1111-1118. 10.1007/s00228-008-0543-1, 18685837.
15. van den Bemt PMLA, Egberts ACG, Lenderink AW, Verzijl JM, Simons KA, van der Pol WSCJM, Leufkens HGM. Risk factors for the development of adverse drug events in hospitalized patients. Pharm World Sci 2000, 22:62-66. 10.1023/A:1008721321016, 10849925.
16. Camargo A, Cardoso Ferreira M, Heineck I. Adverse drug reactions: a cohort study in internal medicine units at a university hospital. Eur J Clin Pharmacol 2006, 62:143-149. 10.1007/s00228-005-0086-7, 16395559.
17. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 2009, 4:e4439. 10.1371/journal.pone.0004439, 2635959, 19209224.
18. Epstein RS, Huang S. The many sides of off-label prescribing. Clin Pharmacol Ther 2012, 91:755-758. 10.1038/clpt.2012.37, 22513307.
19. Knibbe CAJ, Krekels EHJ, Danhof M. Advances in paediatric pharmacokinetics. Expert Opin Drug Metab Toxicol 2011, 7:1-8. 10.1517/17425255.2011.539201, 21117982.
20. Richey RH, Shah UU, Peak M, Craig JV, Ford JL, Barker CE, Nunn AJ, Turner MA. Manipulation of drugs to achieve the required dose is intrinsic to paediatric practice but is not supported by guidelines or evidence. BMC Pediatr 2013, 13:81. 10.1186/1471-2431-13-81, 3691579, 23688279.